DiaMedica Therapeutics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 30 percent increase over losses of $
Diamedica Therapeutics Files Key SEC Report
DiaMedica Therapeutics | 10-Q: Quarterly report
Express News | DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
Diamedica Therapeutics 1Q Loss/Shr 14c >DMAC
Diamedica Therapeutics 1Q Loss/Shr 14c >DMAC
Express News | DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
Bullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of Stock
Diamedica Therapeutics Coverage Assumed by Craig-Hallum at Buy
Diamedica Therapeutics Coverage Assumed by Craig-Hallum at Buy
Express News | Craig-Hallum Assumes DiaMedica Therapeutics at Buy, Announces Price Target of $8
Express News | DiaMedica Therapeutics Inc : Craig-Hallum Assumes Coverage With Buy Rating ; Target Price $8
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI)
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment
DiaMedica Therapeutics (DMAC) said Wednesday it began phase 2/3 testing of its DM199 drug candidate for the treatment of acute ischemic stroke with the dosing of first patient. The company expects to
Express News | DiaMedica Therapeutics Doses First Patient Relaunch Of Pivotal Phase 2/3 ReMEDy2 Trial Of DM199 For Acute Ischemic Stroke
Express News | DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of Its Pivotal Phase 2/3 Remedy2 Trial of Dm199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of Its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica's relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Diamedica Therapeutics Updates SEC Filing
DiaMedica Therapeutics Files for $100M Mixed Securities Shelf
Diamedica Therapeutics Is Maintained at Buy by Craig-Hallum
Diamedica Therapeutics Is Maintained at Buy by Craig-Hallum
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)
No Data